Pfizer (PFE) Raw Materials (2009 - 2019)

Pfizer (PFE) has 11 years of Raw Materials data on file, last reported at $560.0 million in Q1 2019.

• Quarterly Raw Materials fell 32.12% year-over-year to $560.0 million in Q1 2019, while the trailing twelve-month figure through Mar 2019 was $560.0 million (down 32.12% YoY) and the FY2018 annual result came in at $546.0 million, down 30.71% from the prior year.
• Raw Materials rose to $560.0 million in Q1 2019 per PFE's latest filing, from $546.0 million in the prior quarter.
• Across five years, Raw Materials topped out at $950.0 million in Q3 2016 and bottomed at $475.0 million in Q1 2015.
• The 5-year median for Raw Materials is $809.0 million (2016), against an average of $754.1 million.
• The widest annual swing landed in 2016, when Raw Materials soared 84.82%; it then slumped 32.12% in 2019.
• Tracing PFE's Raw Materials over 5 years: stood at $867.0 million in 2015, then fell by 8.54% to $793.0 million in 2016, then slipped by 0.63% to $788.0 million in 2017, then sank by 30.71% to $546.0 million in 2018, then rose by 2.56% to $560.0 million in 2019.
• Per Business Quant, the three latest PFE Raw Materials figures stand at $560.0 million (Q1 2019), $546.0 million (Q4 2018), and $839.0 million (Q3 2018).

Peer Comparison